-
High metastatic potential in mice inheriting a targeted p53 missense mutation.
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4174-9
PMID: 10760284
-
Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation.
Oncogene. 1995 Jul 6;11(1):141-9
PMID: 7624121
-
Restoration of p53 function leads to tumour regression in vivo.
Nature. 2007 Feb 8;445(7128):661-5
PMID: 17251932
-
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
Nature. 1995 Nov 9;378(6553):206-8
PMID: 7477327
-
Adenovirus p53 gene therapy.
Expert Opin Biol Ther. 2006 Jan;6(1):55-61
PMID: 16370914
-
Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.
Dev Biol. 2002 Apr 15;244(2):305-18
PMID: 11944939
-
Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma.
FASEB J. 1993 Jul;7(10):944-50
PMID: 8344492
-
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
PMID: 7568133
-
Cancer gene therapy: an awkward adolescence.
Cancer Gene Ther. 2003 Jul;10(7):501-8
PMID: 12833130
-
Why did p53 gene therapy fail in ovarian cancer?
Lancet Oncol. 2003 Jul;4(7):415-22
PMID: 12850192
-
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
Nat Med. 2002 Mar;8(3):282-8
PMID: 11875500
-
Mdm2 and Mdm4 loss regulates distinct p53 activities.
Mol Cancer Res. 2008 Jun;6(6):947-54
PMID: 18567799
-
Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells.
Mol Cell Biol. 2006 Apr;26(7):2501-10
PMID: 16537896
-
How loops, beta sheets, and alpha helices help us to understand p53.
Cell. 1994 Aug 26;78(4):543-6
PMID: 8069906
-
Intrinsic tumour suppression.
Nature. 2004 Nov 18;432(7015):307-15
PMID: 15549092
-
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
Oncogene. 1991 Sep;6(9):1699-703
PMID: 1923535
-
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
Nature. 1995 Nov 9;378(6553):203-6
PMID: 7477326
-
Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Oncogene. 1994 Jul;9(7):1899-906
PMID: 8208536
-
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
Cell. 1991 May 31;65(5):765-74
PMID: 2040013
-
Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
Cold Spring Harb Symp Quant Biol. 2005;70:489-97
PMID: 16869788
-
Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.
Gene Ther. 2004 Mar;11(6):497-503
PMID: 14762396
-
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
Oncogene. 2001 Jul 5;20(30):4041-9
PMID: 11494132
-
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Cancer Res. 1994 Sep 15;54(18):4855-78
PMID: 8069852
-
The oncogenic roles of p53 mutants in mouse models.
Curr Opin Genet Dev. 2007 Feb;17(1):66-70
PMID: 17208429
-
Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Oncogene. 1996 Sep 19;13(6):1315-22
PMID: 8808706
-
p53 induced growth arrest versus apoptosis and its modulation by survival cytokines.
Cell Cycle. 2007 Jan 15;6(2):166-70
PMID: 17264673
-
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
Science. 1994 Jul 15;265(5170):346-55
PMID: 8023157
-
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Mol Cell Biol. 2007 Aug;27(15):5479-85
PMID: 17526734
-
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Hum Mutat. 2007 Jun;28(6):622-9
PMID: 17311302
-
P53 is a tumor suppressor gene.
Cell. 2004 Jan 23;116(2 Suppl):S67-9, 1 p following S69
PMID: 15055586
-
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Cell. 2004 Dec 17;119(6):847-60
PMID: 15607980
-
Comparative binding of p53 to its promoter and DNA recognition elements.
J Mol Biol. 2005 May 6;348(3):589-96
PMID: 15826656
-
P53 promoter selection: choosing between life and death.
Cell Cycle. 2008 Jan 15;7(2):154-7
PMID: 18212532
-
PUMA, a novel proapoptotic gene, is induced by p53.
Mol Cell. 2001 Mar;7(3):683-94
PMID: 11463392
-
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
J Clin Oncol. 2001 Mar 15;19(6):1750-8
PMID: 11251006
-
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Genes Dev. 2008 May 15;22(10):1337-44
PMID: 18483220
-
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
Cell. 2004 Dec 17;119(6):861-72
PMID: 15607981
-
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
Nature. 2007 Feb 8;445(7128):656-60
PMID: 17251933
-
Modeling the therapeutic efficacy of p53 restoration in tumors.
Cell. 2006 Dec 29;127(7):1323-34
PMID: 17182091
-
Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):95-100
PMID: 11756653
-
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Hum Gene Ther. 1998 Sep 20;9(14):2075-82
PMID: 9759934